Ayala Pharmaceuticals Inc (fka ADXS)

[DewDiligence]

AIM2Cerv will release interim data in mid-2018. That will give a very good indication of how it is going.

The most likely outcome of the interim analysis (at 50% of the events needed for the final analysis) will be a recommendation to continue the trial as planned. In that case, investors won't get additional color on how well AXAL is working.

The above is typical of interim analyses in general—i.e. not specific to AIM2CERV.